Please assess the completion status of the following clinical trial:

Trial Title: Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet diagnosis of mild Alzheimer's disease~* Must have a family member or caregiver who is willing to attend all study visits and provide information on your participation in the study~* If female, must be post-menopausal~* Must be able to swallow tablets~Exclusion Criteria:~* Metal implants or medical devises unsafe for MRI use~* Pre-menopausal female~* HIstory of recent head injury~* Significant major, life-threatening illness or injury (e.g., stroke, AIDS, etc.)~* Vascular dementia or any dementia other than Alzheimer's Disease~* History of significant alcoholism or drug abuse~* History of seizure disorder, developmental delay or major psychiatric illness

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Razadyne ER (Type: EXPERIMENTAL): galantamine treatment group
- Aricept (Type: EXPERIMENTAL): Aricept Treatment Group

Based on this trial design, predict the completion outcome and termination type (if applicable).